Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
EXHTF On Other Exchanges
Symbol
Exchange
EN Paris
Berlin
OTC US
All times are local (Market data is delayed by at least 15 minutes).

diaxonhit (EXHTF) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
71.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DIAXONHIT (EXHTF)

Related News

No related news articles were found.

diaxonhit (EXHTF) Related Businessweek News

No Related Businessweek News Found

diaxonhit (EXHTF) Details

Diaxonhit discovers and commercializes specialty diagnostic products in the transplantation, infectious diseases, and cancer diagnosis specialty areas. Its commercialized product includes Tétanos Quick Stick, a proprietary test, which is used in emergency clinics for the evaluation of the protective status of a patient against tetanus. The company's in-house development products comprise the BJI InoPlex kit, a test that allows the detection of infections linked to articular prosthesis; and EHT Dx15, a test for the diagnosis of thyroid cancer, as well as licensed product includes AlloMap, a gene-expression profiling based blood test for regular and non-invasive surveillance of heart transplant recipients for acute cellular rejection. It is also involved in the development of companion diagnostics for resistant and breast cancers; and tests to monitor the direct effect of drug activity. Diaxonhit was founded in 1997 and is headquartered in Paris, France.

85 Employees
Last Reported Date: 04/30/15
Founded in 1997

diaxonhit (EXHTF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

diaxonhit (EXHTF) Key Developments

Diaxonhit Presents at French Life Science Days conference, Jun-17-2015

Diaxonhit Presents at French Life Science Days conference, Jun-17-2015 . Venue: W Hotel, 541 Lexington Avenue, New York, NY 10022, United States.

DIAXONHIT Announces the Results of a European-Based Clinical Study Confirming the Utility and Performance of the AlloMap® Test

DIAXONHIT announced the results of a European-based clinical study confirming the utility and performance of the AlloMap® test. Results from the CARGO II study, which evaluated the use of AlloMap in 594 heart transplant patients, demonstrated performance similar to previously published experience in the United States. Following a heart transplant procedure, this test enables routine, non-invasive surveillance of acute cellular rejection, thereby assisting clinicians in the care and management of patients. CARGO II (Cardiac Allograft Rejection Gene Expression Observational II) is a prospective, observational, multicenter clinical study. Its main objective was to confirm the results of the first CARGO study, which was used to validate the performance of the AlloMap® test with US patients. CARGO II involved more than 17 centers, 13 of which were located in Europe. These results were the basis for the test's 510K filing with the FDA and CE marking. In the study, blood samples for AlloMap® testing were collected during post-transplant surveillance visits beginning at least 55 days after heart transplantation, with or without cardiac biopsy. After analyzing the samples, the test result was provided as a unique score ranging from 0 to 40, with high values indicating a greater risk of acute cellular rejection. Moderate to severe acute cellular rejection (i.e., histopathology analysis of biopsies showing a grade greater than or equal to 3A according to the ISHLT grading system) were reported by pathologists in 106 out of 3,324 biopsies (3.2%), in 79 out of 594 patients (13.0%). Taking into account these observations, the study shows that the negative predictive value of AlloMap® is greater or equal to 99.0% for AlloMap® scores less than 34. This threshold is therefore associated with a low risk of moderate to severe acute cellular heart graft rejection. Ultimately, the CARGO II results confirm those of the initial CARGO study performed in the United States and demonstrate the utility of AlloMap in ruling out moderate to severe acute cellular allograft rejection.

Diaxonhit Grants Felicitex Therapeutics, Inc. Global Exclusive License

Diaxonhit announced that it granted an exclusive worldwide license to Felicitex Therapeutics Inc. Building upon discoveries made with its SpliceArray proprietary technology, Diaxonhit developed a program targeting the DYRK enzyme, which is involved in several pathogenic pathways related to cell proliferation. Diaxonhit believes this program has a strong potential and found, with Felicitex, a partner who shares the same interest in this innovative approach toward treating cancer. With this agreement, Felicitex acquires the rights for oncology to a lead series of novel small molecule anti-cancer compounds, which are highly active and selective against DYRK as validated by Felicitex in a pancreatic cancer model. The agreement is the culmination of a thorough due diligence process by both sides, as part of which Felicitex evaluated several members of the lead series in vitro and successfully demonstrated proof-of-concept efficacy in vivo in a pancreatic cancer mouse xenograft model.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXHTF:US $0.00 USD 0.00

EXHTF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
NEL ASA 2.34 NOK -0.04
View Industry Companies
 

Industry Analysis

EXHTF

Industry Average

Valuation EXHTF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.3x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIAXONHIT, please visit www.exonhit.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.